Introduction Type 2 diabetes (T2D) is one of the major health concerns affecting 9% of the global population, putting those affected at risk of cardiovascular-associated mortality ( The incretins glucagon-like peptide-1 (GLP-1) and glucose-stimulated insulinotropic polypeptide (GIP) are peptide hormones secreted from intestinal enteroendocrine cells ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
As always, consult your healthcare provider for guidance tailored to your specific needs
The findings came from a large clinical trial led by Virginia Commonwealth University (VCU), which included obese participants with fatty liver disease
doi: 10.3389/fphar.2018.01066
Koussih, L., Atoui, S., Tliba, O
However, breakthroughs can only translate into better patient outcomes if they reach everyone in need